Company / FCF Margin
CRISPR Therapeutics AG FCF Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-9855.5%
FY2025
5-year range
-44484.9% / 50.0%
FY2021-FY2025
Trend
-2441.9%
vs FY2024
Sector context
#129 of 131
Health Care
What the data says
FCF Margin changed -2442% YoY in FY2025, a notable deviation from the 9-year average annual change of -10335%.
Based on SEC 10-K filings.
-9855.5% in FY2025 with a 5-year CAGR of +25850.2%.
Declined from -72.7% to -9855.5% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- +34629.4pp
- 5-Year Change
- +25850.2pp
- 10-Year Change
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 131This company -9855.5% Sector average -646.9%
▼
-1423.4% below sector average
Key checks
Key Insights
- In FY2025, fcf margin decreased 2441.9% year-over-year.
- Currently 9208.6pp below the Health Care sector average.
- Peak fcf margin was recorded in FY2019.
- Lowest fcf margin in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -9855.5% | -2441.9% |
| FY2024 | -387.7% | -433.4% |
| FY2023 | -72.7% | +99.8% |
| FY2022 | -44484.9% | -89105.4% |
| FY2021 | 50.0% | +100.1% |
| FY2020 | -35705.7% | -334.3% |
| FY2019 | 15241.8% | +580.9% |
| FY2018 | -3169.4% | -1567.8% |
| FY2017 | -190.0% | +82.4% |
| FY2016 | -1082.0% | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026